



Archived at the Flinders Academic Commons:

<http://dspace.flinders.edu.au/dspace/>

This is the authors' version of an article accepted for publication in *Palliative Medicine*. The original is available at:

<http://pmj.sagepub.com/content/27/4/320.full>

Please cite this article as: To, T.H.M., Agar, M.R., Shelby-James, T.M., Abernethy, A.P., Doogue, M., Rowett, D., Ko, D. and Currow, D.C., 2012. Off-label prescribing in palliative care – a cross-sectional national survey of Palliative Medicine doctors. *Palliative Medicine*, 27(4), 320-328.

doi: 10.1177/0269216312464263

Copyright © 2012 The Authors

**Please note** that any alterations made during the publishing process may not appear in this version.

**Off-label prescribing in palliative care – a cross-sectional national survey of Australian Palliative Medicine doctors.**

Timothy HM To

Discipline, Palliative & Supportive Services, Flinders University; Southern Adelaide Palliative Services; Department of Rehabilitation & Aged Care, Repatriation General Hospital, Australia

Meera Agar

Palliative Care, Braeside Hospital, Australia; Discipline, Palliative and Supportive Services, Flinders University, Australia

Tania Shelby-James

General practice, Flinders University, Australia

Amy P Abernethy

Department of Medicine, Duke University School of Medicine, USA

Matthew Doogue

Department of Clinical Pharmacology, Flinders Medical Centre; Discipline Clinical Pharmacology, Flinders University, Australia

Debra Rowett

Drug and Therapeutic Information Service, Repatriation General Hospital, Australia

Danielle Ko

Department of Medicine, Massachusetts General Hospital, USA

David C Currow

Discipline, Palliative & Supportive Services, Flinders University, Australia

Corresponding author:

Dr Timothy To, Department of Rehabilitation & Aged Care, Repatriation General Hospital, Daw Park, South Australia, 5041.

Email: [timothy.to@health.sa.gov.au](mailto:timothy.to@health.sa.gov.au)

## **Abstract**

### *Introduction*

Regulatory bodies such as the European Medicines Agency register medications (formulation, route of administration) for specific clinical indications. Once registered, prescription is at each clinician's discretion. *Off-label* use is beyond the registered (licensed) uses. Whilst off-label prescribing is prevalent and, at times, may be clinically appropriate, in many cases detailed evaluation of the efficacy and toxicity is lacking.

### *Methods*

A survey of palliative medicine clinicians examined understanding and practice of off-label prescribing, including unit policies regarding consent and commonly used off-label medication/indication dyads. These dyads were classified into unregistered, off- and on-label, and whether medications were reimbursed.

### *Results*

105 clinicians responded (53% response rate). The majority did not have unit policies on off-label medications, and documented consent poorly. 236 medication/indication dyads were proposed, for 36 medications. 45 dyads (19%) for two medications were unregistered. 118 dyads (50%) for 26 medications were off-label, and the remaining 73 dyads (31%) for 12 medications were on-label.

### *Conclusion*

Off-label prescribing with its clinical, legal and ethical implications is common yet poorly recognised by clinicians. For clinicians, the primary distinction required is understanding the difference between times where:

- quality evidence exists but registration has not been updated by the pharmaceutical sponsors; and
- the evidence has not been generated (or exists and suggests that there is no net benefit).

Further research is required to determine the prevalence, clinical benefit and iatrogenic harm from off-label prescribing in palliative care, in order to determine clinical research priorities or to update registration.

### **Keywords**

Off-label prescribing, drug regulation, physician knowledge, palliative care, iatrogenic harm

## Introduction

In Australia, the Therapeutic Goods Administration (TGA) has a similar role to the European Medicines Agency (EMA) in Europe and Food and Drug Administration (FDA) in the United States in registering *medications* (formulation, strength and route of administration) for specific *indications* (population and disease). However once the medication has been approved, the clinician prescribes and may choose to use the medication in an *off-label* (unlicensed) manner – i.e. an unapproved dose, route of administration and/or indication. This is distinct from an *unregistered medication* that is not approved by the regulatory authorities for any indication in their jurisdiction.

Off-label prescribing occurs in three contexts in clinical practice:<sup>1</sup>

1. When approval does not extend to cover the particular dose or indication, although evidence of efficacy is available - often because evidence became available after the medication was registered or after patent has expired, and the label has not been updated;
2. In areas of medicine where high-level evidence is difficult to generate, even for treatments which are likely to be effective, or because there is a lack of a commercial imperative eg. rare diseases where adequately powered clinical trials are impossible, or new indications for medications are now out of patent. In these situations there may be compelling biological plausibility and/or lower level evidence to support prescribing; or
3. When the medication is proven to be ineffective or there is no reason to believe it is effective.

Off-label prescribing is prevalent in many fields of medicine including: general medicine,<sup>2</sup> psychiatry,<sup>3</sup> obstetrics,<sup>4</sup> paediatrics,<sup>5-7</sup> oncology,<sup>8-10</sup> HIV/AIDS<sup>11</sup> and palliative care.<sup>12,13</sup> Off-label prescribing is best documented in paediatrics, with prevalence of 11% in general practice, 72% in a neonatal intensive care unit,<sup>5,14,15</sup> and up to 89% of paediatric inpatients.<sup>16</sup> In other populations, estimates of off-label prescribing vary: 8% in psychiatry inpatients,<sup>3</sup> 21% in office-based physicians,<sup>2</sup> 40% in HIV patients,<sup>11</sup> and up to 65% in oncology patients.<sup>10,17,18</sup>

In palliative care, patients often have multiple pathologies and complex symptoms, are frequently on multiple medications<sup>19</sup> and have fragile and rapidly changing health states. Adequately designed clinical trials in this population are feasible but challenging. Consequently, many medications used in palliative care are prescribed off-label in a setting where drug-host and drug-drug interactions<sup>20</sup> are already likely. Patients may also have limited ability to provide informed consent for off-label medications.<sup>21</sup>

Pavis and Wilcock examined the off-label use of medications in palliative care in the United Kingdom in 2001 against General Medical Council (GMC) recommendations, finding low rates of verbal or written consent and poor documentation of reasons for off-label use in case notes.<sup>13</sup> Whilst these GMC recommendations have since been updated,<sup>22</sup> the questions asked remain by Pavis and Wilcock remain pertinent to quality prescribing. The aim of this study was to examine off-label prescribing in Australian palliative medicine clinicians through a national point prevalence survey.

## Methods

### 1. Study setting

Specialist palliative care services (SPCS) in Australia span a range of different service delivery models, from large regional multidisciplinary teams to single clinical nurses in small rural locations. SPCS may include public and private hospitals with inpatient and/or consultative services, free-standing palliative care units, outpatient clinics and community care teams. SPCS may be the primary health

provider but more commonly work in consultation to support general practitioners, other specialists and community services.

### *Study design and participants*

This cross-sectional study was part of a larger survey looking at prescribing practices. The survey included: participants' demographics, scopes of palliative medicine practice, level of experience, and perceptions and experience of off-label prescribing for the three medications in each respondent's practice that he/she most often used off-label (Appendix 1).

An invitation to participate, with a printed version of the survey, was sent in July 2010 to all Australian-based members of the Australia and New Zealand Society of Palliative Medicine (ANZSPM), a medical society open to doctors with an interest in palliative medicine. The letter included a link to the online survey.

### *Data collection*

Survey data were entered by participants using the online survey tool, or if completed on paper were entered by an administrative assistant.

### *Data analysis*

Medication registration and listed indications were obtained from the Australian TGA website ([www.tga.gov.au](http://www.tga.gov.au), accessed 9<sup>th</sup> August 2011). All nominated medication/indication dyads, were classified as unregistered, off-label or on-label. In Australia, whilst the TGA regulates medication approval, the Pharmaceutical Benefits Scheme (PBS) determines medication subsidy – ie. medications approved by the TGA do not automatically receive subsidy from the PBS, and if not, patients must pay full price. Given this distinction and the potential to misconstrue on-label but unsubsidised dyads as off-label, on-label dyads were also grouped into subsidised and unsubsidised ([www.pbs.gov.au](http://www.pbs.gov.au), accessed 9<sup>th</sup> August 2011). Uncertainty in interpretation of listed indications were reviewed by the authors and consensus reached. As the TGA consider any medication registered for parenteral use can be given intravenously, intramuscularly, or subcutaneously if administerable without dilution, route of administration was not considered separately in the analysis. Nominated indications by survey respondents were grouped for the purpose of analysis (e.g. nausea/vomiting, pain, delirium/agitation).

Data were analysed using PWAS 18.0 (SPSS Corp. Inc., 2008. Chicago, IL. USA). Descriptive statistics were used to analyse categorical variables, and comparisons using Chi-square test or Fisher's exact test as appropriate.

The reporting of this survey complies with the STROBE criteria for reporting cross-sectional studies.<sup>23</sup> Ethical approval for this study was granted by the Flinders University Social and Behavioural Research Ethics Committee.

## **Results**

In July 2010, 213 of 220 registered ANZSPM members had a valid contact address and of these, 105 (49%) provided valid responses for analysis. Thirty-nine percent were male and >74% of the population were aged >40 years. The majority had been practising medicine for more than ten years (91%), and Palliative Medicine for more than five years (78%). Respondents worked in a variety of settings – acute inpatient (35%), hospital liaison (64%), community (46%), outpatient (46%) and palliative care unit (55%). Most respondents (91%) saw >60 new patients per year.

The majority of respondents reported that their services did not have, or were unaware of, a policy on providing information to patients about the off-label use of medications (89%), nor consistently limited the use of off-label use of medications to consultants (70%). The documentation of consent, verbal or written, was variable but tended to be absent or inconsistent (Table 1). When asked to quantify the number of occasions verbal or written consent was obtained, or reasons documented in the notes, the number of occasions reported was frequently much lower than expected given the numbers of patients seen (Table 2). For example, eight of the ten respondents who reported always documenting reasons for off-label prescribing saw >100 patients per year with life-limiting illnesses. However when asked to quantify consent and documentation, only seven gave a count of verbal or written consent, with six of the seven reporting ten or less occasions; furthermore the five respondents who gave a count of documenting in the notes all reported this ten or less times. Overall, 20% of respondents never obtained verbal nor written consent, nor documented a reason for off-label use.

The 105 respondents proposed 236 off-label medication/indication dyads for 36 medications (Figure 1, Table 3). Forty-five (19%) dyads for two medications were unregistered (cyclizine and levomepromazine (methotrimeprazine) are not registered in Australia). One hundred and eighteen (50%) dyads were off-label, covering 26 medications for 38 indications. The remaining 73 (31%) dyads were on-label, covering 12 medications for 14 indications. Of these 73 on-label dyads, 31 were of pregabalin or gabapentin for pain, which are registered but not subsidised indications (off-subsidy use).

## **Discussion**

This study has found that palliative care practitioners have a poor understanding of medication regulations and the status of frequently used medications. When asked about “licensed drugs for unlicensed uses”, only 50% of nominated medication/indication dyads were correct.

Nineteen percent of the dyads were unregistered. Previous registration for cyclizine and levomepromazine has expired, and given their limited general use and low commercial value, their sponsors have declined to update and renew their registration. However, these medications are available in Australia using the Special Access Scheme, allowing importation of unregistered medications.

The remaining 31% dyads were on-label. Respondents may have mistaken on-label but unsubsidised medications with off-label use. Furthermore, a number of nominated dyads may have been designated off-label because the route (eg. subcutaneous) was believed off-label. This reflects poor understanding of medication regulation processes that lead to a medication being off-label.

This poor understanding may be, in part, due to a widespread lack of service policies to guide off-label prescribing. Only 11% of respondents reported that their service had policies for the use of off-label medications, however this was more than British palliative care services (2%) a decade ago<sup>13</sup> but less than American academic medical centres (17%)<sup>24</sup> and Italian hospices (28%).<sup>25</sup> The practices for off-label prescribing are reportedly better than for Pavis and Wilcock, with 26% of respondents in this study never seeking verbal consent (compared with 38%) and 76% never seeking written consent (compared with 93%), though never documenting reasons still occurred in approximately 50% of cases.<sup>13</sup> Whilst there may have been some improvement in practices around off-label prescribing since 2001, this survey demonstrates there are still large deficits though 100% compliance may not be necessary.<sup>22</sup> Establishing a robust policy is a first step, but compliance with these policies is likely to be extremely limited given responses reflected into this survey.

## **What are the issues around off-label prescribing?**

### *Clinically*

Off-label prescribing is not a new issue.<sup>26,27</sup> Whilst some cases of off-label prescribing is clinically appropriate, studies have demonstrated that off-label prescribing:

- is poorly recognised,<sup>28</sup>
- may lack adequate informed consent processes,<sup>29,30</sup>
- lacks the efficacy achieved in on-label prescribing,<sup>31,32</sup> and
- is more likely to be associated with increased or unrecognised adverse events.<sup>33-35</sup>

And whilst off-label prescribing may have benefits, these must be weighed against harms to define the net clinical effect.

### *Ethically*

The community reasonably expects that prescribing will be for indications approved by reputable regulatory authorities, supported by high quality evidence, and any deviation from this will be supported by robust policy and informed consent.<sup>36</sup> Off-label medication use may blur the distinction between clinical practice and experimentation, creating significant ethical concerns.<sup>37</sup> Prescribers must understand the potential harms and benefits of a particular therapy (including uncertainties), any alternative therapeutic options and facilitate informed shared decision making with the patient.

### *Legally*

Once a medication is registered, off-label use is a matter of medical judgement, shifting the focus of ethical and legal responsibility (and hence liability) from manufacturers/suppliers to the prescribing practitioner.<sup>1,38,39</sup> Prescribing off-label is not *prima facie* evidence of medical negligence – negligence requires that the off-label use of the medication for the particular patient was not in line with a reasonable standard of medical care.<sup>40</sup> Regulations prohibit the promotion of off-label uses of medications however historically there has been: omission or understating of risks, of overstating effectiveness, and of unjustifiable comparative claims for off-label medication use.<sup>41-43</sup>

### **Why does off label prescribing exist?**

The TGA, EMEA and FDA regulate prescription medication marketing, not clinician nor institutional prescribing.<sup>28,43</sup> Given the substantial resources required and evidence base needed to register a medication or update its indications there will always be off-label prescribing.<sup>44</sup> In some cases this is supported by studies that underpin particular off-label indications, but regulatory approval has not been sought to cover the indication, dose or route of administration.<sup>29,45</sup>

There are examples where off-label uses of medications have provided patients with improved outcomes, or where such prescribing genuinely reflects leading edge clinical care.<sup>46</sup> Often this is where off-label prescribing was biologically plausible and supported by clinical evidence, although for yet unregistered indications. Examples include imatinib for gastrointestinal stromal tumours,<sup>47</sup> morphine for dyspnoea,<sup>48</sup> and immunomodulators in chronic autoimmune/inflammatory conditions.

Expanding indications, or 'indication creep', may provide important therapeutic efficacy data, however measuring net clinical effect requires systematic assessment of benefits and harms.<sup>49,50</sup>

The risk is that practitioners expand indications with limited scientific rationale while the pharmaceutical industry either passively observes broadening indications or actively promotes off-label use even in the absence of evidence of efficacy and safety.<sup>50</sup>

Prescribing is strongly influenced by local practice, anecdote or expert opinion, which may not always reflect best evidence.<sup>51,52</sup> A study of American office-based physicians found that 73% of off-label prescribing had little or no scientific support.<sup>2</sup> Furthermore, as demonstrated in this study,

many practitioners do not know whether or not they are working with registered indications, even in their area of specialty practice.<sup>28</sup>

### **Off-label prescribing in palliative care?**

The available literature on off-label prescribing in palliative care suggests that 12-26% of prescriptions are off-label,<sup>12,25,53</sup> with low rates of system-level strategies to address off-label prescribing.<sup>25</sup> Off-label prescribing may be biologically plausible, as with octreotide for malignant bowel obstruction, or supported by high-level evidence, as in the case of morphine for dyspnoea.

A number of factors have hindered the building of an evidence base for prescribing in palliative care. This population is often considered difficult to study, due to declining and unstable health, comorbidities, cognitive dysfunction, and 'gate-keeping' to 'protect' patients from clinical trials perceived too burdensome despite patient and caregiver support.<sup>54-56</sup> Many of the medications commonly used in palliative care are off patent, and thus there is little incentive for further research or to expand registration when definitive studies emerge.

### *Limitations*

This study relies on self-report with no easy way to provide third party verification of the data presented. Furthermore, given the demonstrated poor understanding of off-label prescribing, respondents' self-report may not reflect the extent of their off-label prescribing and likely to underestimate the prevalence. Furthermore the sample may be biased, with respondents potentially those most conscious of issues surrounding off-label use and therefore the estimates are a more positive picture than the day-to-day reality. Without accurate quantification of the prevalence of off-label prescribing, the interpretation of these data is limited.

### *Implications for practice*

Ethical off-label use requires at least one of the following:

- existing high-level evidence;
- in the setting of a properly designed rigorous clinical trial; or
- exceptional use justified by individual clinical circumstances.<sup>29</sup>

To evaluate the appropriateness of off-label medication use, proposed frameworks consider the level of evidence available and give guidance as to the level of consent, pharmacovigilance, and ongoing review required (Figure 2).<sup>22,29,37,57</sup> As with any treatment decision, but especially pertinent in cases with low certainty of net clinical effect, a process of shared decision making with the patient is required. This should include disclosure of the nature of off-label use, the benefits and harms, the evidence to support the off-label use, and why in the particular patient's circumstances, the prescriber believes there is no equivalent or better TGA/EMA approved alternative.<sup>36,57</sup> This should be supported by documentation of the informed consent process and discussion in the medical notes.<sup>57,58</sup>

Given the uncertainties of benefits or harms, there is a need to specify treatment goals and to monitor net clinical effect at intervals determined by expected time to response, and requirements for medication titration.<sup>44,59,60</sup> Ideally formal review of efficacy, safety and cost outcomes should occur to guide further practice.<sup>37</sup> As a minimum, prospective data should be collected on the net clinical effects of the off-label use of medications, and such data aggregated.<sup>61</sup>

Whilst changing clinician behaviour can be difficult,<sup>51</sup> provision of valid evidence and interventions targeting prescribing have been shown to change clinician understanding and prescribing behaviour.<sup>50,62</sup> Other potential strategies include requiring the primary indication when prescribing, which would facilitate post-marketing surveillance.<sup>63</sup> Reducing administrative and financial barriers to approving new indications for registered medications would remove key obstacles to updating



registration without lessening the level of evidence required. Professional and regulatory bodies can also guide health policy and influence clinician prescribing.<sup>57</sup> The role of the pharmaceutical industry in promoting off-label prescribing has become more widely recognised in recent cases such as gabapentin,<sup>64</sup> oxycodone<sup>65</sup> and erythropoietin,<sup>66</sup> and substantial penalties have been imposed in an attempt to discourage such actions.<sup>67</sup>

### *Implications for research*

A lack of evidence of effect does not equate to evidence of ineffectiveness. There needs to be prioritisation of research to improve the evidence for medications used off-label in palliative care, particularly those: used frequently, with high cost, with significant potential benefits and/or harms, or with little supporting evidence.<sup>68,69</sup> Accurate, prospective determination of the prevalence of off-label prescribing in palliative care, and the medications used, will help guide studies to improve the evidence base.

With regular monitoring of prescribing practice, emerging medication/indication dyads can be identified and appropriate studies performed to build an evidence base. At a minimum, pharmacokinetic studies could be performed in healthy volunteers, but ideally comparative effectiveness studies to identify efficacy compared to non-pharmacological and on-label options, but also systematically address iatrogenic harm, toxicity and cost-effectiveness, giving an indication of net clinical effect. Should a medication/indication dyad prove beneficial, the dyad should be submitted to the regulatory bodies for registration. Ongoing post-registration evaluation of benefits and harms is required to ensure that the medication is performing as expected.

Further work is required on strategies to optimise prescribing practices, and to develop policies around off-label use of medications.

### **Conclusion**

Off-label prescribing in Australian palliative medicine clinicians is poorly recognised and has clinical, legal and ethical implications for the management of palliative care patients.

Two key questions need to be asked in considering off-label use of medications:

- Does quality evidence exist but registration has not been updated by the pharmaceutical sponsors?; and
- Has the evidence not been generated (or exists and suggests that there is no net clinical benefit)?

For clinicians, categorising the medication under one of these two scenarios will guide appropriateness and level of consent, and this should be complemented with subsequent pharmacovigilance for net clinical effect. For policy makers and funding bodies, medications used off-label where there is insufficient evidence should be targeted for further research with a view to updating registration if subsequent studies demonstrate net clinical benefit. More research is required to determine the prevalence and clinical consequences of off-label prescribing in palliative care and to direct intervention for clinicians and patients.

### **Funding**

This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors

**Appendix 1.** Survey of the use of licensed drugs for un-licensed uses in palliative care.

**Section 3: Use of licensed drugs for un-licensed uses in palliative care**

**Does your service operate a policy on providing information to patients and their carers about the prescribing of licensed drugs for un-licensed uses/routes?**

- Yes
- No

	Always	Sometime	Never
Do you limit the prescribing of un-licensed drugs in this way to consultants only?	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Do you obtain verbal consent from the patient/caregiver?	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Do you obtain written informed consent from the patient/caregiver?	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Do you document in your notes when you are using drugs outside of their license and the reasons for this?	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>

If you answered “*sometimes*” to any of the above please answer the following questions

**How often have you obtained verbal or written informed consent from patients/caregivers to use licensed drugs for un-licensed use/routes in the last 6 months?**

Times

**How often have you documented in the notes the reasons for using unlicensed drugs for un-licensed use/routes in the last 6 months?**

Times

**Please list the top three licensed drugs for un-licensed use / routes that you use, their indication, and routes of administration.**

	Drug	Indication	Route of administration
Drug 1	<input type="text"/>	<input type="text"/>	<input type="text"/>
Drug 2	<input type="text"/>	<input type="text"/>	<input type="text"/>
Drug 3	<input type="text"/>	<input type="text"/>	<input type="text"/>

Table 1. Respondents' practices regarding off-label prescribing and associated verbal or written consent, and documentation of reasons.

	Always (%)	Sometimes (%)	Never (%)
Do you limit off-label prescribing to consultants only?	29 (29)	39 (39)	31 (31)
Do you obtain verbal consent from the patient/caregiver?	24 (24)	49 (50)	26 (26)
Do you obtain written consent from the patient/caregiver?	1 (1)	23 (24)	74 (76)
Do you document in your notes when prescribing off-label & the reasons for this?	10 (10)	38 (39)	49 (51)

Table 2. Number of occasions of verbal or written informed consent, and documentation of the reason in the notes for off-label prescribing in the last six months.

Number of occasions	Verbal or written consent <sup>†</sup> n=67	Documentation in notes <sup>‡</sup> n=54
0	18 (27%)	23 (43%)
1-5	17 (25%)	18 (33%)
6-10	17 (25%)	10 (19%)
>10	15 (22%)	3 (6%)

<sup>†</sup>38/105 (36%) had no response

<sup>‡</sup>51/105 (49%) had no response

Table 3. Top nominated medication/indication dyads categorised by unregistered medication, off-label use, and on-label use.

Unregistered	Indication	n	Off-label	Indication	n	On-label	Indication	n
Levomepromazine	Nausea/vomiting	19	Ketamine	Pain	24	Haloperidol	Nausea/vomiting	22
	Delirium/agitation	2	Octreotide	Malignant bowel obstruction	20	Gabapentin	Pain	19
	Sedation	1		Nausea/vomiting	2	Pregabalin	Pain	12
	Dyspnoea	1	Clonazepam	Delirium/agitation	7	Midazolam	Sedation	4
	Blank	1		Sedation	6		Agitation	2
Cyclizine	Nausea/vomiting	19		Anxiety	3	Metoclopramide	Nausea/vomiting	5
	Malignant bowel obstruction	1		Pain	2			
	Blank	1		Distress	1			
			Olanzapine	Delirium/agitation	5			
				Nausea/vomiting	3			
			Midazolam	Anxiety	4			
				Dyspnoea	2			
				Pain	1			
			Morphine	Dyspnoea	6			





Figure 1. Nominated medication/indication dyads categorised by unregistered, off-label and on-label (n=236).

Figure 2. Assessing appropriateness of off-label medicines use<sup>29</sup>



## References

1. Casali PG. The off-label use of drugs in oncology: a position paper by the European Society for Medical Oncology (ESMO). *Ann Oncol* 2007;18:1923-5.
2. Radley DC, Finkelstein SN, Stafford RS. Off-label prescribing among office-based physicians. *Arch Intern Med* 2006;166:1021-6.
3. Douglas-Hall P, Fuller A, Gill-Banham S. An analysis of off-licence prescribing in psychiatric medicine. *Pharm J* 2001;267:890-1.
4. Herring C, McManus A, Weeks A. Off-label prescribing during pregnancy in the UK: an analysis of 18,000 prescriptions in Liverpool Women's Hospital. *Int J Pharm Pract* 2010;18:226-9.
5. McIntyre J, Conroy S, Avery A, Corns H, Choonara I. Unlicensed and off label prescribing of drugs in general practice. *Arch Dis Child* 2000;83:498-501.
6. Mason J, Pirmohamed M, Nunn T. Off-label and unlicensed medicine use and adverse drug reactions in children: a narrative review of the literature. *Eur J Clin Pharmacol* 2011.
7. Conroy S, Choonara I, Impicciatore P, et al. Survey of unlicensed and off label drug use in paediatric wards in European countries. European Network for Drug Investigation in Children. *BMJ* 2000;320:79-82.
8. Mellor JD, Bensted KE, Chan PL. Off label and unlicensed prescribing in a specialist oncology center in Australia. *Asia-Pacific J of Clin Oncol* 2009;5:242-6.
9. Poole SG, Dooley MJ. Off-label prescribing in oncology. *Support Care Cancer* 2004;12:302-5.
10. Abernethy AP, Raman G, Balk EM, et al. Systematic review: reliability of compendia methods for off-label oncology indications. *Ann Intern Med* 2009;150:336-43.
11. Brosgart CL, Mitchell T, Charlebois E, et al. Off-label drug use in human immunodeficiency virus disease. *J Acquir Immune Defic Syndr Hum Retrovirol* 1996;12:56-62.
12. Atkinson CV, Kirkham SR. Unlicensed uses for medication in a palliative care unit. *Palliat Med* 1999;13:145-52.
13. Pavis H, Wilcock A. Prescribing of drugs for use outside their licence in palliative care: survey of specialists in the United Kingdom. *BMJ* 2001;323:484-5.
14. Avenel S, Bomkratz A, Dassieu G, Janaud JC, Danan C. [The incidence of prescriptions without marketing product license in a neonatal intensive care unit]. *Arch Pediatr* 2000;7:143-7.
15. Cuzzolin L, Zaccaron A, Fanos V. Unlicensed and off-label uses of drugs in paediatrics: a review of the literature. *Fundam Clin Pharmacol* 2003;17:125-31.
16. Pandolfini C, Impicciatore P, Provasi D, Rocchi F, Campi R, Bonati M. Off-label use of drugs in Italy: a prospective, observational and multicentre study. *Acta Paediatr* 2002;91:339-47.
17. Oncology ASoC. Reimbursement for Cancer Treatment: Coverage of Off-Label Drug Indications. *J Clin Oncol* 2006;24:3206-8.
18. Soares M. "Off-Label" Indications for Oncology Drug Use and Drug Compendia: History and Current Status. *J Oncol Pract* 2005;1:102-5.
19. Currow DC, Stevenson JP, Abernethy AP, Plummer J, Shelby-James TM. Prescribing in palliative care as death approaches. *J Am Geriatr Soc* 2007;55:590-5.
20. Currow DC, To THM, Abernethy AP. Prescribing at Times of Clinical Transition in Chronic Or Progressive Diseases. *Int J Gerontol* 2009;3:1-8.
21. Dietz I, Borasio GD, Schneider G, Jox RJ. Medical errors and patient safety in palliative care: a review of current literature. *J Palliat Med* 2010;13:1469-74.
22. Good practice in prescribing medicines - guidance for doctors. 2008. (Accessed 12th June 2012, at [http://www.gmc-uk.org/guidance/ethical\\_guidance/prescriptions\\_faqs.asp#10](http://www.gmc-uk.org/guidance/ethical_guidance/prescriptions_faqs.asp#10).)
23. von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP; STROBE Initiative.



The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies.

*J Clin Epidemiol.* 2008 Apr;61(4):344-9.

24. Ansani N, Branch R, Fedutes-Henderson B, et al. United States medical practice summary: innovative off-label medication use. *Am J Med Qual* 2006;21:246-54.
25. Toscani F, Di Giulio P, Campi R, Pellerin I, De Luca A, Casale G. Off-Label Prescriptions in Italian Hospices: A National Survey. *J Pain Symptom Manage* 2009;38:365-71.
26. Anon. Use of approved drugs for unlabeled indications. *FDA Drug Bull* 1982;12:4-5.
27. Shapiro SA. Limiting physician freedom to prescribe a drug for any purpose: the need for FDA regulation. *Northwest Uni Law Rev* 1979;73:801-72.
28. Chen DT, Wynia MK, Moloney RM, Alexander GC. U.S. physician knowledge of the FDA-approved indications and evidence base for commonly prescribed drugs: results of a national survey. *Pharmacoepidemiol Drug Saf* 2009;18:1094-100.
29. Gazarian M, Kelly M, McPhee JR, Graudins LV, Ward RL, Campbell TJ. Off-label use of medicines: consensus recommendations for evaluating appropriateness. *Med J Aust* 2006;185:544-8.
30. Currow DC. Why don't we do more rigorous clinical research so that we can stop experimenting on patients? *J Palliat Med* 2010;13:636-7.
31. Gazarian M. Why are children still therapeutic orphans? *Austr Presc* 2003;26:122-3.
32. Mack A. Examination of the evidence for off-label use of gabapentin. *J Manag Care Pharm* 2003;9:559-68.
33. Turner S, Nunn AJ, Fielding K, Choonara I. Adverse drug reactions to unlicensed and off-label drugs on paediatric wards: a prospective study. *Acta Paediatr* 1999;88:965-8.
34. Neubert A, Dormann H, Weiss J, et al. The impact of unlicensed and off-label drug use on adverse drug reactions in paediatric patients. *Drug Saf* 2004;27:1059-67.
35. Anon. Evidence of harm from off label or unlicensed medicines in children. London: European Medicines Agency (EMA); 2004.
36. Wilkes M, Johns M. Informed consent and shared decision-making: a requirement to disclose to patients off-label prescriptions. *PLoS Med* 2008;5:e223.
37. Ansani N, Sirio C, Smitherman T, et al. Designing a strategy to promote safe, innovative off-label use of medications. *Am J Med Qual* 2006;21:255-61.
38. Blum RS. Legal considerations in off-label medication prescribing. *Arch Intern Med* 2002;162:1777-9.
39. Thomadsen BR, Heaton HT, 2nd, Jani SK, et al. Off-label use of medical products in radiation therapy: summary of the report of AAPM Task Group No. 121. *Med Phys* 2010;37:2300-11.
40. Henry V. Off-label prescribing. Legal implications. *J Legal Med* 1999;20:365-83.
41. Anon. Prescription drugs: FDA's oversight of the promotion of drugs for off-label uses. In: Office USGA, ed. Report to the ranking member, Committee on Finance, US Senate 2008.
42. Anon. Good Reprint Practices for the Distribution of Medical Journal Articles and Medical or Scientific Reference Publications on Unapproved New Uses of Approved Drugs and Approved or Cleared Medical Devices. Silver Spring, MD: Food and Drug Administration; 2009.
43. Joseph JN, Deaton D, Ehsan H, Bonanno MA. Enforcement related to off-label marketing and use of drugs and devices: where have we been and where are we going? *J Health Life Sci Law* 2009;2:73-108.
44. Healy D, Nutt D. Prescriptions, licences and evidence. *Psychiatr Bull* 1998;22:680-4.
45. Wertheimer A. Off-label prescribing of drugs for children. *Curr Drug Saf* 2011;6:46-8.
46. Bright JL. Positive outcomes through the appropriate use of off-label prescribing. *Arch Intern Med* 2006;166:2554-5; author reply 5.
47. Joensuu H, Roberts PJ, Sarlomo-Rikala M, et al. Effect of the Tyrosine Kinase Inhibitor STI571 in a Patient with a Metastatic Gastrointestinal Stromal Tumor. *N Engl J Med* 2001;344:1052-6.

48. Abernethy AP, Currow DC, Frith P, Fazekas BS, McHugh A, Bui C. Randomised, double blind, placebo controlled crossover trial of sustained release morphine for the management of refractory dyspnoea. *BMJ* 2003;327:523-8.
49. Edlin R, Round J, Hulme C, McCabe C. Cost-effectiveness analysis and efficient use of the pharmaceutical budget: the key role of clinical pharmacologists. *Br J Clin Pharmacol* 2010;70:350-5.
50. Fullerton CA, Busch AB, Frank RG. The rise and fall of gabapentin for bipolar disorder: a case study on off-label pharmaceutical diffusion. *Med Care* 2010;48:372-9.
51. Oxman AD, Thomson MA, Davis DA, Haynes RB. No magic bullets: a systematic review of 102 trials of interventions to improve professional practice. *CMAJ* 1995;153:1423-31.
52. Flodgren G, Parmelli E, Doumit G, et al. Local opinion leaders: effects on professional practice and health care outcomes. *Cochrane Database Syst Rev* 2011:CD000125.
53. Todd J, Davies A. Use of unlicensed medication in palliative medicine. *Palliat Med* 1999;13:446-.
54. White C, Gilshenan K, Hardy J. A survey of the views of palliative care healthcare professionals towards referring cancer patients to participate in randomized controlled trials in palliative care. *Support Care Cancer* 2008;16:1397-405.
55. White CD, Hardy JR, Gilshenan KS, Charles MA, Pinkerton CR. Randomised controlled trials of palliative care - a survey of the views of advanced cancer patients and their relatives. *Eur J Cancer* 2008;44:1820-8.
56. White C, Hardy J. What do palliative care patients and their relatives think about research in palliative care?-a systematic review. *Support Care Cancer* 2010;18:905-11.
57. Largent EA, Miller FG, Pearson SD. Going off-label without venturing off-course: evidence and ethical off-label prescribing. *Arch Intern Med* 2009;169:1745-7.
58. Edersheim JG, Stern TA. Liability associated with prescribing medications. *Prim Care Companion J Clin Psychiatr* 2009;11:115-9.
59. Quill TE, Holloway R. Time-limited trials near the end of life. *JAMA* 2011;306:1483-4.
60. Abernethy AP, Currow DC. Time-Limited Trials. *JAMA* 2012;307:33-4.
61. Currow DC, Rowett D, Doogue M, To TH, Abernethy AP. An international initiative to create a collaborative for pharmacovigilance in hospice and palliative care clinical practice. *J Palliat Med* 2012;15:282-6.
62. Price DW, Raebel MA, Conner DA, Wright LA, Carroll NM. Pharmaceuticals from development to practice: learnings from an online curriculum. *Am J Manag Care* 2009;15:e109-14.
63. Eguale T, Winslade N, Hanley JA, Buckeridge DL, Tamblyn R. Enhancing pharmacovigilance with systematic collection of treatment indication in electronic prescribing: a validation study in Canada. *Drug Saf* 2010;33:559-67.
64. Landefeld CS, Steinman MA. The Neurontin Legacy — Marketing through Misinformation and Manipulation. *N Engl J Med* 2009;360:103-6.
65. Van Zee A. The Promotion and Marketing of OxyContin: Commercial Triumph, Public Health Tragedy. *Am J Public Health* 2009;99:221-7.
66. Hébert PC, Stanbrook M. Indication creep: physician beware. *CMAJ* 2007;177:697.
67. Almashat S, Preston C, Waterman T, Wolfe S. Rapidly increasing criminal and civil monetary penalties against the pharmaceutical industry: 1991 to 2010: Public Citizen's Health Research Group; 2010.
68. Currow DC, Shelby-James TM, Agar M, et al. Planning phase III multi-site clinical trials in palliative care: the role of consecutive cohort audits to identify potential participant populations. *Support Care Cancer* 2010;18:1571-9.
69. Walton SM, Schumock GT, Lee KV, Alexander GC, Meltzer D, Stafford RS. Prioritizing future research on off-label prescribing: results of a quantitative evaluation. *Pharmacotherapy* 2008;28:1443-52.